PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Umeda T. Drug Saf Case Rep. Feb 2018; 5(1): 8 Pubmed, Volltext, Springer [10328]
Umehara KI. Biopharm Drug Dispos. Mar 2018; 39(3): 152-163 Pubmed [7602]
Unadkat, Chien. Pharm Res (1988)5 (Suppl), S177 [1795]
Ung D. Xenobiotica. Oct 2009; 39(10): 749-56 Pubmed [7364]
Unger M. Drug Metab Rev. Aug 2013; 45(3): 353-85 Pubmed [8012]
Unger NR. Expert Opin Pharmacother. Dec 2016; 17(17): 2359-2370 Pubmed [7245]
Unglaub et al. (2002) Psychiatr Prax 30: Suppl. 2: S121-124 [1163]
Unglaub et al. (2003) Psychiatr Prax 30 (Suppl. 2): S121-S124 [1149]
Unholzer S. Pharmacopsychiatry. Sep 2015; 48(6): 211-4 Pubmed [743]
Uno T. Br J Clin Pharmacol. Mar 2006; 61(3): 309-14 Pubmed, Volltext, DOI [7705]
Unterecker S. Int Clin Psychopharmacol. Jul 2014; 29(4): 206-11 Pubmed, Volltext, DOI [3077]
Unterecker S. J Clin Psychopharmacol. Aug 2013; 33(4): 561-4 Pubmed [4698]
Upadya GM. Indian J Med Sci. Oct 2009; 63(10): 461-3 Pubmed [9154]
Upreti VV. Br J Clin Pharmacol. Jul 2011; 72(1): 92-102 Pubmed, Volltext, DOI [5775]
Uprima (Apomorphine). Abott Laboratories Ltd. Summary of Product Characteristics, May 2001 [1960]
Uprima (Apomorphine). Abott Laboratories Ltd. Summary of Product Charakteristics, May 2001 [833]
Upton A. Biol Blood Marrow Transplant. Jul 2007; 13(7): 760-4 Pubmed, Volltext, DOI [8241]
Upton RA. Clin Pharmacokinet. Jan 1991; 20(1): 66-80 Pubmed [5711]
Urban AE. Psychiatr Danub. Sep 2015; 27 Suppl 1: S459-61 Pubmed [1142]
Urbanek C, Jockers-Scherübl MC, Vorsicht Pflanze!, NEUROTRANSMITTER 4/2006: 87-88 [3344]
Urbano & Ware (2008) J Clin Psychopharmacol 28:704-705 [2235]
Uriel A. Int J STD AIDS. Dec 2011; 22(12): 768 Pubmed [7116]
Urits I. Neurol Ther. Dec 2020; 9(2): 403-417 Pubmed [13511]
Urits I. Pain Ther. Jun 2020; 9(1): 195-215 Pubmed [13510]
Ursing J. Antimicrob Agents Chemother. Feb 2020; 64(3) Pubmed, Volltext, DOI [9022]
Urva S. J Clin Pharmacol. Apr 2013; 53(4): 444-50 Pubmed [8973]
US-Prescribing information for FIRMAGON® [3874]
Usall J. J Clin Psychiatry. Jun 2014; 75(6): 608-15 Pubmed [9792]
Usiskin SI. Am J Psychiatry. Jun 2000; 157(6): 1021 Pubmed [1114]
Usta NG. Ther Adv Psychopharmacol. Dec 2014; 4(6): 276-81 Pubmed, Volltext, DOI [8155]
Ustianowski A. Expert Rev Anti Infect Ther. Dec 2022; 20(12): 1517-1527 Pubmed [13423]
Üstün Bezgin S. Int Arch Otorhinolaryngol. Jul 2019; 23(3): e267-e275 Pubmed [11409]
Ustuner MA. Tissue Cell. Dec 2017; 49(6): 691-696 Pubmed [11233]
Uthman BM. Epilepsia. Jan 1989; 30 Suppl 2: S33-7 Pubmed [10614]
Uttamsingh V. Drug Metab Dispos. Nov 2005; 33(11): 1723-8 Pubmed [290]
Uzaraga I. Support Care Cancer. Jul 2012; 20(7): 1515-24 Pubmed [12076]
Uzun M. Eur Rev Med Pharmacol Sci. Mar 2009; 13(2): 95-8 Pubmed [10088]
Vadlamudi RS. South Med J. Jul 2007; 100(7): 720-4 Pubmed [6978]
Vadlapatla RK. Expert Opin Drug Metab Toxicol. Apr 2014; 10(4): 561-80 Pubmed, Volltext, DOI [4005]
Vaduganathan M. J Card Fail. Nov 2021; 27(11): 1280-1284 Pubmed [12674]
Vaidyanathan S. Clin Pharmacokinet. Jan 2008; 47(8): 515-31 Pubmed [8099]
Vainer JL, Chouinard G. Caffeine and antipsychotics. Clin Invest Med (1993) 16 (Suppl 4), B20 [1097]
Vainer JL. J Clin Psychopharmacol. Aug 1994; 14(4): 284-5 Pubmed [1094]
Vairo G. J Med. Jan 1984; 15(1): 75-80 Pubmed [10490]
Vakkalagadda B. Am J Cardiovasc Drugs. Apr 2016; 16(2): 119-27 Pubmed [6139]
Vakkalagadda et al. Am J Cardiovasc Drugs. 2016 Jan 9 [4138]
Valassi E. J Clin Endocrinol Metab. Mar 2010; 95(3): 1025-33 Pubmed [10949]
Valdes L. Arch Pediatr. Jun 1997; 4(6): 535-7 Pubmed [8948]
Valdes M. J Affect Disord. Mar 2019; 246: 861-866 Pubmed [9888]
Vale JA. Lancet. Jun 1991; 337(8756): 1552 Pubmed [1279]
Valin N. J Int Assoc Physicians AIDS Care (Chic). Mar 2009; 8(2): 113-21 Pubmed [6380]
Valk-Swinkels CG. Ned Tijdschr Geneeskd. Jan 2013; 157(28): A5667 Pubmed [6215]
Vallée A. Aging (Albany NY). Feb 2020; 12(3): 3095-3113 Pubmed [11454]
Vallejo R. Pain Physician. Jul 2011; 14(4): E343-60 Pubmed [3301]
Valsalan VC. Br Med J (Clin Res Ed). Jul 1982; 285(6337): 261-2 Pubmed, Volltext [6788]
Van Berkel MA. Pharmacotherapy. Jun 2013; 33(6): e96-100 Pubmed [6132]
van Breemen RB. Fitoterapia. Jan 2011; 82(1): 38-43 Pubmed [12297]
van Breemen RB. J Agric Food Chem. May 2020; 68(18): 5212-5220 Pubmed [9109]
van Dalem J. BMJ. Jul 2016; 354: i3625 Pubmed, Volltext, DOI [9026]
van de Wetering-Krebbers SF. Drug Metab Dispos. Apr 2011; 39(4): 580-90 Pubmed [250]
van den Bemt PM. Pharm World Sci. Oct 2002; 24(5): 201-4 Pubmed [11830]
van den Berg MJ. Am J Ther. Jan 2016; 23(1): e246-8 Pubmed [1592]
Van den Bergh A. Clin Pharmacokinet. Sep 2020; 59(9): 1149-1160 Pubmed [11495]
Van der Auwera P. J Antimicrob Chemother. Nov 1993; 32 Suppl B: 103-15 Pubmed [5908]
van der Bol JM. Clin Cancer Res. Jan 2010; 16(2): 736-42 Pubmed [5010]
Van der Heijden KB. J Am Acad Child Adolesc Psychiatry. Feb 2007; 46(2): 233-41 Pubmed [11710]
van der Klauw MM. Arch Intern Med. Feb 1999; 159(4): 369-74 Pubmed [9089]
van der Kuy PH. BMJ. Feb 1998; 316(7129): 441 Pubmed, Volltext [1954]
van der Lee M. Antivir Ther. Jan 2007; 12(7): 1127-32 Pubmed [6482]
van der Lee MJ. Antimicrob Agents Chemother. Nov 2007; 51(11): 4098-104 Pubmed, Volltext, DOI [10143]
van der Lee MJ. Clin Pharmacol Ther. Aug 2006; 80(2): 159-68 Pubmed [8755]
van der Sandt IC. AIDS. Mar 2001; 15(4): 483-91 Pubmed [4997]
van der Velden W. Neth J Med. May 2008; 66(5): 204-6 Pubmed [5870]
van der Watt JJ. Int J Tuberc Lung Dis. Nov 2015; 19(11): 1312-9 Pubmed [9404]
van der Weide K. J Clin Psychopharmacol. Jun 2015; 35(3): 228-36 Pubmed [193]
van der Zalm IJB. J Med Case Rep. Jun 2020; 14(1): 83 Pubmed [11309]
van Dijkman SC. Br J Clin Pharmacol. Jan 2018; 84(1): 97-111 Pubmed, Volltext, DOI [9427]
Van Es MA. Amyotroph Lateral Scler Frontotemporal Degener. Nov 2020; 21(7-8): 584-592 Pubmed [11457]
van Giersbergen PL. Clin Pharmacol Ther. Mar 2007; 81(3): 414-9 Pubmed [4289]
van Giersbergen PL. Int J Clin Pharmacol Ther. Mar 2006; 44(3): 113-8 Pubmed [4287]
van Gorp F. Br J Clin Pharmacol. Mar 2012; 73(3): 402-10 Pubmed [13801]
van Haarst AD. Clin Pharmacol Ther. Nov 1998; 64(5): 542-6 Pubmed [5324]
van Harten et al. Eur Neuropsychopharmacol (1992) 2, 381 [1462]
van Harten J. Clin Pharmacokinet. Jan 1995; 29 Suppl 1: 1-9 Pubmed [325]
van Harten J. Clin Pharmacol Ther. Oct 1992; 52(4): 427-35 Pubmed [1457]
van Heeswijk RP. Antivir Ther. Jan 2013; 18(4): 553-60 Pubmed [6322]
van Heeswijk RP. J Antimicrob Chemother. Sep 2014; 69(9): 2310-8 Pubmed [5184]
van Heeswijk RP. J Clin Pharmacol. Jul 2006; 46(7): 758-67 Pubmed [461]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7391]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7392]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7393]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7394]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7395]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7396]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7397]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7398]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7399]
van Helvoort M. Int Clin Psychopharmacol. Sep 2019; 34(5): 269-272 Pubmed [9131]
van Hoppe S. Pharmacol Res. Aug 2019; 146: 104297 Pubmed [11487]
van Hoppe S. Pharmacol Res. Jun 2017; 120: 43-50 Pubmed [7756]